Drug Trial Radar · NCT01764633
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Last checked: Nov 20, 2026Latest source record: May 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27,564
Actual
Start
Feb 8, 2013
Primary completion
Nov 11, 2016
Study completion Nov 11, 2016
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Jan 9, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective was to evaluate the effect of treatment with evolocumab, compared with placebo, on the risk for cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization, whichever occurs first, in patients with clinically evident cardiovascular disease.
Conditions
- Dyslipidemia
Interventions
EvolocumabBiological
Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
PlaceboDrug
Administered subcutaneously using a spring-based prefilled 1.0 mL autoinjector/pen.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Cardiovascular Death, Myocardial Infarction, Hospitalization for Unstable Angina, Stroke, or Coronary RevascularizationTime frame: Events that occurred from randomization to the last confirmed survival status date; the median duration of follow-up was 26 months. KM estimates at 6, 12, 18, 24, 30 and 36 months are reported.
Locations
1,284 sites in 49 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Birmingham, Alabama
Research Site
Huntsville, Alabama
Research Site
Mobile, Alabama
Research Site
Anchorage, Alaska
Research Site
Glendale, Arizona
Research Site
Phoenix, Arizona
Research Site
Phoenix, Arizona
Research Site
Phoenix, Arizona
Research Site
Tucson, Arizona
Research Site
Tucson, Arizona
Research Site
Alhambra, California
Research Site
Banning, California
Research Site
Beverly Hills, California
Research Site
Encino, California
Research Site
Escondido, California
Research Site
Glendale, California
Research Site
Harbor City, California
Research Site
Huntington Beach, California
Research Site
Laguna Hills, California
Research Site
Long Beach, California
Research Site
Long Beach, California
Research Site
Los Alamitos, California
Research Site
Los Angeles, California
Research Site
Los Angeles, California
Research Site
Newport Beach, California
Research Site
Oceanside, California
Research Site
Oxnard, California
Research Site
Palm Springs, California
Research Site
Roseville, California
Research Site
Sacramento, California
Research Site
San Diego, California
Research Site
San Diego, California
Research Site
San Pedro, California
Research Site
Santa Ana, California
Research Site
Tarzana, California
Research Site
Thousand Oaks, California
Research Site
Torrance, California
Research Site
Torrance, California
Research Site
Valley Village, California
Showing 40 of 1,284 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.